Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy

Published:2023-10 Issue:1 Volume:165 Page:79-90
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Hou Chongxian,Shi Shenbao,Gao Mengjiao,Ji Jingsen,Ma Chengcheng,Wang Tianwei,Chen Taoliang,Liu Yang,Zhong Jiasheng,Zheng Yaofeng,Ye Jing’an,Ke Yiquan

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Medical Scientific Research Foundation of Dongguan People's Hospital under Grant

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-023-04449-6.pdf

Reference36 articles.

1. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–84. https://doi.org/10.1016/S1470-2045(15)70076-8

2. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665

3. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312–22. https://doi.org/10.1016/S1470-2045(17)30065-7

4. Medikonda R, Dunn G, Rahman M, Fecci P, Lim M (2021) A review of glioblastoma immunotherapy. J Neurooncol 151(1):41–53. https://doi.org/10.1007/s11060-020-03448-1

5. Xu S, Tang L, Li X, Fan F, Liu Z (2020) Immunotherapy for glioma: current management and future application. Cancer Lett 476:1–12. https://doi.org/10.1016/j.canlet.2020.02.002

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the potential of regulated cell death in glioma treatment: a focus on autophagy-dependent cell death, anoikis, ferroptosis, cuproptosis, pyroptosis, immunogenic cell death, and the crosstalk between them;Frontiers in Oncology;2024-08-09

2. TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms;Pharmacological Research;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3